Prognostic factors in children with membranoproliferative glomerulonephritis type I.
The clinical outcome of patients with membranoproliferative glomerulonephritis (MPGN) varies, with some patients progressing to end-stage renal disease. The aim of this retrospective study was to analyze the initial clinical signs and laboratory test results associated with an MPGN prognosis. The study cohort consisted of 47 patients with idiopathic MPGN Type I treated at the National Institute of Pediatrics, Mexico City, between 1971 and 2001. The median follow-up was 3 years. The three different outcomes of interest were death, renal failure, and nephrotic syndrome. The patients' ages ranged between 4 and 16 years. All patients had different degrees of proteinuria, hyperlipidemia, and microscopic/macroscopic hematuria, and 85.1% of them showed hypocomplementemia. Clinical outcomes varied, however, the most common was nephrotic syndrome, either alone or combined with other syndromes, which accounted for 74.5% of all cases. Fifteen patients died. Treatment with methylprednisolone improved the patient's condition, while the use of chloroquine or cyclophosphamide worsened it. Twenty-two patients had some degree of renal failure; glomerular filtration rate (GFR) levels and albumin values were negatively associated to renal failure, while treatment with methylprednisolone decreased the probability of renal failure. Nephrotic syndrome persisted in 18 patients; hemolytic complement and hemoglobin values were negatively associated with nephrotic syndrome, while macroscopic hematuria was positively associated with it. Signs that suggested a poor prognosis during diagnosis were low GFR, low albumin, low hemolytic complement, and macroscopic hematuria. Treatment with methylprednisolone seemed to improve prognosis, however, this needs to be confirmed with randomized studies.
García-de la Puente
Silvestre
S
Department of Nephrology, National Institute of Pediatrics, Ministry of Health, Mexico City, Mexico. garciadelapuente@hotmail.com
Orozco-Loza
Iraida Luz
IL
Zaltzman-Girshevich
Samuel
S
de Leon Bojorge
Beatriz
B
D000293:Adolescent; D000477:Alkylating Agents / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D002738:Chloroquine / Q000009:adverse effects; D003165:Complement System Proteins / Q000032:analysis; D003520:Cyclophosphamide / Q000009:adverse effects; D018450:Disease Progression; D005260:Female; D005919:Glomerular Filtration Rate; D015432:Glomerulonephritis, Membranoproliferative / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000401:mortality; D005938:Glucocorticoids / Q000627:therapeutic use; D006417:Hematuria / Q000209:etiology; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008800:Mexico / Q000453:epidemiology; D009404:Nephrotic Syndrome / Q000097:blood / Q000188:drug therapy / Q000209:etiology* / Q000401:mortality; D051437:Renal Insufficiency / Q000097:blood / Q000188:drug therapy / Q000209:etiology* / Q000401:mortality; D012189:Retrospective Studies; D012307:Risk Factors; D012709:Serum Albumin / Q000032:analysis; D013997:Time Factors; D016896:Treatment Outcome
D000477:Alkylating Agents; D005938:Glucocorticoids; D006454:Hemoglobins; D012709:Serum Albumin; D002738:Chloroquine; D003520:Cyclophosphamide; D003165:Complement System Proteins; D008775:Methylprednisolone